Equilibrio entre la innovación y el gasto público sanitario: El caso particular de los medicamentos biosimilares
Biosimilar medicines have been commercialized in the European regulatory territory for thirteen years. Its commercialization has not been exempted from multiple criticisms, especially the confusions about its erroneous equivalence with generic medicines and the doubts generated regarding its possibi...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | Gaztelania |
| Argitaratua: |
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://dialnet.unirioja.es/servlet/oaiart?codigo=7671618 |
| Baliabidea: | Revista Derecho del Estado, ISSN 0122-9893, Nº. 48 (Enero-Abril), 2021, pags. 273-296 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe: Izan zaitez lehena erregistro honi etiketa jartzen
|